HOME >> MEDICINE >> NEWS
NIAID Ebola vaccine enters human trial

searchers will also examine the volunteers' blood to look for signs of immune system reaction to the vaccine. Ultimately, the scientists envision this vaccine as the first in a two-stage vaccination strategy called prime-boost: after "priming" with the DNA vaccine, the immune system response is "boosted," or augmented, by a second inoculation with modified, non-disease-causing cold viruses that make selected Ebola proteins. The booster essentially sets the immune system on alert against future infection by Ebola virus.

In August, Dr. Nabel and his colleagues reported using the booster shot to quickly and completely protect monkeys against Ebola. A fast-acting vaccine would be of great use during an outbreak of Ebola. The full prime-boost strategy, which uses the DNA vaccine being tested in this study, elicits a stronger immune response and is important to pursue for individuals at high risk, such as health care workers. Dr. Nabel says that expanded human trials of Ebola vaccines using the prime-boost strategy could begin by 2005.


'"/>

Contact: Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
18-Nov-2003


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAID Ebola vaccine enters human trial

(Date:8/28/2015)... ... ... The newest therapy to receive orphan drug status for the treatment of ... to educational website Surviving Mesothelioma. Click here to read their article on ... week from the FDA, will now head into Phase I clinical trials to establish ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ECP or EECP, ... External Counterpulsation (EECP or ECP) machines with a full clinic licence to help people ... since 2007 helping people prevent and reverse heart disease through its evidence-based ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life ... of the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and ... over the last three years, PREVENT ranks higher on the list than any other ...
(Date:8/28/2015)... ... August 28, 2015 , ... Santa Rosa was recently recognized, for the ... Modern Healthcare. In the KLAS “2015 Midterm Performance Review: Software & Services”, Santa Rosa ... recognitions from Modern Healthcare and KLAS are directly related to our company culture.” said ...
(Date:8/27/2015)... ... August 28, 2015 , ... ... out of foster care through “The Language of Flowers,” has joined the Youth ... work, particularly the organization’s YVLifeSet program, was piqued by her passion for helping ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2Health News:Santa Rosa Consulting Recognized by Modern Healthcare as One of the Top 100 Best Places to Work and from KLAS Research with the Highest Rating for Go-Live Support 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 3
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 ... announced that its shareholders have approved Mylan,s proposed ... ; TASE) and the related issuance of Mylan ... general meeting of shareholders held today. The transaction ... the extraordinary general meeting. In addition, the transaction ...
(Date:8/28/2015)... and LONDON , August 28, ... approach seamlessly connects people, ... improving outcomes and the cost ... PHG AEX: PHIA) today announced its presence at  ESC ... cardiology solutions, including Heart Model A.I. , EchoNavigator and IntelliSpace ...
(Date:8/27/2015)... , Aug. 27, 2015 DURECT Corporation ... scheduled to present at three upcoming healthcare conferences.  ... and CEO, will present at the Rodman & Renshaw ... Eastern time. The conference is being held at the ... . A live audio webcast of the presentation ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2
Cached News: